We are live on
!
Find out more
GPP
Great Point Partners Portfolio holdings
AUM
$435M
1-Year Est. Return
318.81%
This Fund
S&P 500
This Quarter
Est. Return
-8.19%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$417M
AUM Growth
+$3.18M
(+0.77%)
Cap. Flow
+$36.7M
Cap. Flow
% of AUM
8.81%
Top 10 Holdings %
Top 10 Hldgs %
53.86%
Holding
43
New
13
Increased
11
Reduced
7
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$17.1M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$14.3M |
| 3 |
Nektar Therapeutics
NKTR
|
+$13.2M |
| 4 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
+$11.3M |
| 5 |
Precision BioSciences
DTIL
|
+$11.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exelixis
EXEL
|
+$29.5M |
| 2 |
BCYC
Bicycle Therapeutics
BCYC
|
+$24.2M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$22.2M |
| 4 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$17.1M |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.09% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KDNY
26
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $5.89M | 1.41% |
336,731
-1,086,951
| -76% | -$17.1M |
|
|
VTYX
27
DELISTED
Ventyx Biosciences
VTYX
| $4.76M | 1.14% |
389,223
+52,889
| +16% | +$790K |
|
|
SLN
28
Silence Therapeutics
SLN
$495M
| $4.76M | 1.14% |
401,449
-42,994
| -10% | -$522K |
|
|
PVLA
29
Palvella Therapeutics
PVLA
$1.99B
| $4.7M | 1.13% |
31,406
+3,918
| +14% | +$715K |
|
|
ALPN
30
DELISTED
Alpine Immune Sciences Inc
ALPN
| $4.58M | 1.1% |
+538,819
| New | +$4.64M |
|
|
ETNB
31
DELISTED
89bio
ETNB
| $4.51M | 1.08% |
+1,400,000
| New | +$4.23M |
|
32
Pliant Therapeutics
PLRX
$64.4M
| $2.86M | 0.69% |
+357,263
| New | +$2.29M |
|
33
MoonLake Immunotherapeutics
MLTX
$1.57B
| $2.27M | 0.54% |
+432,000
| New | +$2.72M |
|
34
Dianthus Therapeutics
DNTH
$5.84B
| $1.4M | 0.34% |
73,125
| – | – |
|
35
Spyre Therapeutics
SYRE
$8.54B
| $1.26M | 0.3% |
+100,000
| New | +$3.5M |
|
36
Ardelyx
ARDX
$1.22B
| – | – |
-4,761,905
| Closed | -$5.09M |
|
|
BCYC
37
Bicycle Therapeutics
BCYC
$269M
| – | – |
-550,592
| Closed | -$24.2M |
|
|
38
Exelixis
EXEL
$13.3B
| – | – |
-1,300,000
| Closed | -$29.5M |
|
|
39
CALL
Nektar Therapeutics
NKTR
$2.39B
| – | – |
-6,667
| Closed | -$539K |
|
40
Passage Bio
PASG
$14.4M
| – | – |
-5,695
| Closed | -$353K |
|
41
Rafael Holdings
RFL
$101M
| – | – |
-122,694
| Closed | -$304K |
|
|
42
Rigel Pharmaceuticals
RIGL
$681M
| – | – |
-400,000
| Closed | -$12M |
|
|
43
Vertex Pharmaceuticals
VRTX
$121B
| – | – |
-85,000
| Closed | -$22.2M |
|
Similar funds
GDS
JWM
SWG
SCP
VIM
VDBMI
ACG
TECP
Great Point Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Great Point Partners held 43 positions worth $417M, up 0.77% from $414M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Great Point Partners deployed $36.7M of net new capital in Q2 2022, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Karuna Therapeutics, Inc. Common Stock: 149,000 shares worth $18.9M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier, followed by Real Estate.
On the sell side, the largest reduction was Chinook Therapeutics, Inc. Common Stock, an estimated $17.1M trimmed.
- Great Point Partners's largest Q2 2022 buy was Karuna Therapeutics, Inc. Common Stock: 149,000 shares worth $18.9M.
- Great Point Partners added most to CinCor Pharma, Inc. Common Stock in Q2 2022, an estimated $11.3M increase.
- Great Point Partners's biggest Q2 2022 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $17.1M.
- Great Point Partners fully exited Exelixis in Q2 2022, selling an estimated $29.5M.
- Great Point Partners's ten largest holdings make up 54% of its $417M portfolio in Q2 2022.
- Great Point Partners opened 13 new positions and closed 8 in Q2 2022.
- Great Point Partners's portfolio value rose 0.77% quarter-over-quarter to $417M.
Based on Great Point Partners's 13F filing for Q2 2022, filed 15 Aug 2022.